24.04

0.58% -0.1797

Beam Therapeutics Inc (BEAM)

Overview News Price History Option Chain Financials Why BEAM Down? Discussions Forecast

Beam Therapeutics Inc stock is traded at $24.04, with a volume of 232.77K. It is down -0.58% in the last 24 hours and down -16.07% over the past month. Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

Previous Close:

$24.22

Open:

$23.52

24h Volume:

232.77K

Relative Volume:

0.12

Market Cap:

$2.45B

Revenue:

$139.74M

Net Income/Loss:

$-79.99M

P/E Ratio:

-23.67

EPS:

-1.0157

Net Cash Flow:

$-360.05M

1W Performance:

+1.95%

1M Performance:

-16.07%

6M Performance:

-5.90%

1Y Performance:

+30.30%

1-Day Range:

$23.52

$24.36

1-Week Range:

$21.63

$25.30

52-Week Range:

$13.53

$36.44

Beam Therapeutics Inc Stock (BEAM) Company Profile

Name

Beam Therapeutics Inc

Sector

Healthcare (1116)

Industry

Biotechnology (621)

Phone

857-327-8775

Address

26 LANDSDOWNE STREET, CAMBRIDGE, MA

Employee

511

Twitter

Next Earnings Date

2024-11-05

Latest SEC Filings

BEAM's Discussions on Twitter

Compare BEAM vs VRTX, REGN, ARGX, ALNY, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BEAM Beam Therapeutics Inc	24.08	2.47B	139.74M	-79.99M	-360.05M	-1.0157
VRTX Vertex Pharmaceuticals Inc	443.71	113.62B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.38	82.17B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	748.02	46.12B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	318.52	43.60B	3.71B	313.75M	465.38M	2.2571
INSM Insmed Inc	161.63	35.54B	606.42M	-1.28B	-997.58M	-6.403

Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-20-26	Initiated	Canaccord Genuity	Buy
Oct-09-25	Initiated	Jefferies	Buy
Mar-28-25	Upgrade	BofA Securities	Neutral → Buy
Mar-10-25	Upgrade	Scotiabank	Sector Perform → Sector Outperform
Jan-29-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Nov-06-24	Upgrade	Leerink Partners	Market Perform → Outperform
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Jul-23-24	Initiated	H.C. Wainwright	Buy
Jan-29-24	Upgrade	JP Morgan	Neutral → Overweight
Dec-15-23	Downgrade	BofA Securities	Buy → Neutral
Dec-08-23	Downgrade	Jefferies	Buy → Hold
Oct-20-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Oct-20-23	Downgrade	Leerink Partners	Outperform → Market Perform
Mar-21-23	Initiated	Bernstein	Mkt Perform
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight
Dec-20-22	Upgrade	BMO Capital Markets	Market Perform → Outperform
Dec-13-22	Initiated	Citigroup	Buy
Jun-17-22	Initiated	BMO Capital Markets	Market Perform
Apr-28-22	Initiated	Credit Suisse	Neutral
Jan-05-22	Initiated	Guggenheim	Buy
Oct-19-21	Initiated	SVB Leerink	Outperform
Sep-24-21	Resumed	Stifel	Buy
Sep-10-21	Initiated	BofA Securities	Buy
May-11-21	Initiated	Redburn	Buy
May-04-21	Initiated	RBC Capital Mkts	Sector Perform
Mar-01-21	Downgrade	Barclays	Overweight → Equal Weight
Feb-16-21	Initiated	Wells Fargo	Overweight
Jan-29-21	Downgrade	JP Morgan	Overweight → Neutral
Jan-06-21	Initiated	Stifel	Hold
Aug-05-20	Initiated	William Blair	Outperform
Mar-02-20	Initiated	Barclays	Overweight
Mar-02-20	Initiated	JP Morgan	Overweight
Mar-02-20	Initiated	Jefferies	Buy
Mar-02-20	Initiated	Wedbush	Outperform

View All

Beam Therapeutics Inc Stock (BEAM) Latest News

Apr 01, 2026

Beam Therapeutics publishes sickle cell therapy trial data By Investing.com - in.investing.com

Apr 01, 2026

In 31 sickle cell patients, Beam saw no severe pain crises after risto-cel - Stock Titan

Apr 01, 2026

Mar 31, 2026

[144] Beam Therapeutics Inc. SEC Filing - Stock Titan

Mar 31, 2026

ETRADE Financial (NASDAQ: BEAM) insider sales and restricted vesting - Stock Titan

Mar 31, 2026

BEAM (NASDAQ: BEAM) affiliate notifies sale of 25,000 shares via option exercise - Stock Titan

Mar 31, 2026

Beam to advance gene-editing drug to pivotal development - msn.com

Mar 31, 2026

Beam Therapeutics shares climb after positive BEAM-302 trial update - MSN

Mar 31, 2026

Mar 30, 2026

BEAM (NASDAQ: BEAM) insider schedules 25,000-share sale after option exercise - Stock Titan

Mar 30, 2026

Mar 29, 2026

Beam Therapeutics gains on clinical update as gene therapy hits protective protein levels - msn.com

Mar 29, 2026

Mar 28, 2026

(BEAM) Risk Channels and Responsive Allocation - Stock Traders Daily

Mar 28, 2026

JPMorgan Chase & Co. Has $13.14 Million Stock Position in Beam Therapeutics Inc. $BEAM - MarketBeat

Mar 28, 2026

Risk Recap: Is Beam Therapeutics Inc a cyclical or defensive stock2026 Levels & Long-Term Growth Plans - baoquankhu1.vn

Mar 28, 2026

Mar 27, 2026

BEAM Stock's Gains Fade Despite Promising Data Rare Liver Disease Treatment Data - Stocktwits

Mar 27, 2026